EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetic Profiles of Lansoprazole in Patients With Morbid Obesity Post‐Roux‐en‐Y Gastric Bypass Surgery

Suthep Udomsawaengsup iD, Sathienrapong Chantawibul iD, Naranon Boonyuen, Sarunnuch Panyavorakhunchai iD, Pattharasai Kachornvitaya iD, Wasu Wisanuyothin iD, Pittawat Somvanapanich, Warittha Lertwatthiphong, Napatsanan Tanathitiphuwarat, Pajaree Chariyavilaskul iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70200 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Suthep Udomsawaengsup und 9 weiteren Autor:innen. Beteiligte Einrichtung: Treatment of Obesity and Metabolic Disease Research Unit, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Lansoprazole, Obesity, Morbid, Gastric Bypass, Proton Pump Inhibitors. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the Ratchadapiseksomphot Fund, Faculty of Medicine, Chulalongkorn University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Data on the effects of Roux‐en‐Y gastric bypass (RYGB) surgery on lansoprazole pharmacokinetics in morbidly obese patients are limited. This study aimed to evaluate the impact of RYGB surgery on the pharmacokinetic profile of lansoprazole in Thai morbidly obese patients. Participants received 30 mg of lansoprazole twice daily for 7 days before surgery and continued the regimen for 6 weeks post‐surgery. Plasma lansoprazole concentrations were measured at predose (0), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, and 8 h after dosing, both pre‐ and post‐surgery, using a validated high‐performance liquid chromatography technique. CYP2C19 genotyping classified participants as normal metabolizers ( *1 / *1 ) or intermediate metabolizers ( *1 / *2 and *1 / *3 ). Pharmacokinetic parameters, including the area under the plasma concentration‐time curve from 0 to 8 h (AUC 0–8 h ), maximum plasma concentration (Cmax), and time to maximum concentration (Tmax), were compared before and after surgery. A total of 13 patients (mean age 37.0 ± 3.9 years; body mass index 54.0 ± 4.8 kg/m 2 ) were enrolled. Post‐surgery, AUC 0–8 h and Cmax decreased by 16% ( p = 0.009) and 31% ( p = 0.003), respectively, while Tmax remained unchanged. A 30% reduction in Cmax ( p = 0.007) was observed in CYP2C19 normal metabolizers, whereas no significant changes were noted in intermediate metabolizers. In conclusion, RYGB surgery significantly reduced lansoprazole systemic exposure, particularly in CYP2C19 normal metabolizers. Further studies are needed to explore the clinical implications of these pharmacokinetic changes and develop optimized treatment strategies for post‐RYGB patients. Trial Registration: ClinicalTrials.gov identifier: TCTR20220118001

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LansoprazoleObesity, MorbidGastric BypassProton Pump InhibitorsHumansFemaleMaleAdultCytochrome P-450 CYP2C19Middle AgedArea Under CurveGenotypeTreatment Outcome

Stichwörter der Autor:innen

Roux‐en‐Y gastric bypasslansoprazolemorbid obesitypharmacokinetics

Substanzen

LansoprazoleCytochrome P-450 CYP2C19CYP2C19 protein, humanProton Pump Inhibitors

Autor:innen und Institutionen

  • Treatment of Obesity and Metabolic Disease Research Unit, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Center of Excellence in Clinical Pharmacokinetics and Pharmacogenomics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Pharmacogenomic Laboratory, Center for Medical Diagnostic Laboratories, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
  • Department of Pharmacology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

ORCID-Profile: Suthep Udomsawaengsup, Sathienrapong Chantawibul, Sarunnuch Panyavorakhunchai, Pattharasai Kachornvitaya, Wasu Wisanuyothin, Pajaree Chariyavilaskul

Förderung

  • the Ratchadapiseksomphot Fund, Faculty of Medicine, Chulalongkorn University

Zitieren

APA

Udomsawaengsup, S., Chantawibul, S., Boonyuen, N., Panyavorakhunchai, S., Kachornvitaya, P., Wisanuyothin, W., Somvanapanich, P., Lertwatthiphong, W., Tanathitiphuwarat, N., & Chariyavilaskul, P. (2025). Pharmacokinetic Profiles of Lansoprazole in Patients With Morbid Obesity Post‐Roux‐en‐Y Gastric Bypass Surgery. Clinical and Translational Science. https://doi.org/10.1111/cts.70200

Vancouver

Udomsawaengsup S, Chantawibul S, Boonyuen N, Panyavorakhunchai S, Kachornvitaya P, Wisanuyothin W, et al. Pharmacokinetic Profiles of Lansoprazole in Patients With Morbid Obesity Post‐Roux‐en‐Y Gastric Bypass Surgery. Clinical and Translational Science. 2025. doi:10.1111/cts.70200

BibTeX
@article{Udomsawaengsup2025,
  author = {Udomsawaengsup, Suthep and Chantawibul, Sathienrapong and Boonyuen, Naranon and Panyavorakhunchai, Sarunnuch and Kachornvitaya, Pattharasai and Wisanuyothin, Wasu and Somvanapanich, Pittawat and Lertwatthiphong, Warittha and Tanathitiphuwarat, Napatsanan and Chariyavilaskul, Pajaree},
  title = {Pharmacokinetic Profiles of Lansoprazole in Patients With Morbid Obesity Post‐Roux‐en‐Y Gastric Bypass Surgery},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70200}
}
Kostenlos starten →